ArticleStem cells international2026
Derivation and Pluripotency Validation of Six iPSC Lines From Amniotic Fluid Carrying Intermediate α-Thalassemia Genotypes (--
Article in Stem cells international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Derivation and Pluripotency Validation of Six iPSC Lines From Amniotic Fluid Carrying Intermediate α-Thalassemia Genotypes (--Stem cells international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Thalassemia intermedia (TI), or hemoglobin H (Hb H) disease, presents significant clinical heterogeneity, and its pathogenesis remains unclear. This study aimed to establish induced pluripotent stem cells (iPSCs) from amniotic fluid (AF) cells of fetuses diagnosed with intermediate α-thalassemia genotypes (-α Methods: AF cells from six TI fetuses were reprogrammed using nonintegrating episomal vectors via electro-transfection. The resulting iPSC lines underwent comprehensive characterization, including alkaline phosphatase (AP) staining, immunofluorescence (IF) for pluripotency markers (e.g., OCT-4, SOX-2, and TRA-1-60), quantitative reverse transcription real-time PCR (RT-qPCR) for the expression of pluripotency genes, G-band karyotyping, and genetic analysis for thalassemia. Differentiation potential was assessed in vivo via teratoma formation in immunodeficient mice and in vitro through directed hematopoietic differentiation. Results: Six stable iPSC lines were successfully established. All lines retained the progenitor's intermediate α-thalassemia genotype and exhibited normal karyotypes. They displayed typical embryonic stem cell (ESC)-like morphology, were positive for AP, and expressed key pluripotency markers. In vivo, all lines robustly formed teratomas containing tissues derived from all three germ layers (endoderm, mesoderm, and ectoderm). Furthermore, in vitro hematopoietic differentiation protocols successfully induced the iPSCs to generate CD34 Conclusion: We have successfully derived and comprehensively characterized six patient-specific iPSC lines from intermediate α-thalassemia fetuses. These cell lines demonstrate robust pluripotency and maintain the capacity for hematopoietic differentiation. They represent a valuable resource for investigating TI pathophysiology, screening novel drugs, and developing future cell-based therapeutic strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.